GlassScriptPhysician profile
Jason M Collins
NPI 1427265826
$4,326.75
in general payments reported to CMS, 2019-2025
22 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.36 · 2021: $11.98 · 2022: $155 · 2023: $686 · 2024: $1,546 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,936.22 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,797.52 | 2021-2025 | Rinvoq, Linzess, Viberzi |
| Gilead Sciences, INC. | $355.00 | 2024-2025 | Livdelzi |
| Genzyme Corporation | $329.52 | 2023-2024 | |
| Janssen Biotech, INC. | $271.62 | 2022-2025 | Stelara, Tremfya |
| Biocon Biologics INC | $185.34 | 2025 | Yesintek |
| Takeda Pharmaceuticals U.S.A., INC. | $184.03 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $161.90 | 2024-2025 | Resmetirom, Rezdiffra |
| Pfizer INC. | $154.45 | 2024-2025 | |
| Qol Medical, LLC | $120.67 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.36 | 2022-2023 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $107.68 | 2024-2025 | |
| Boston Scientific Corporation | $101.86 | 2019-2024 | Orcapod |
| Aimmune Therapeutics, INC. | $94.28 | 2024-2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $64.40 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $56.55 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54.49 | 2025 | Voquezna |
| Ardelyx, INC. | $53.16 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $34.94 | 2025 | Iqirvo |
| Lilly USA, LLC | $27.58 | 2025 | Omvoh |
| Exact Sciences Corporation | $26.94 | 2025 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $21.03 | 2025 | Sutab, Suflave |
| Novo Nordisk INC | $14.43 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.